# A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency

> **NCT05676853** · PHASE3 · TERMINATED · sponsor: **Aeglea Biotherapeutics** · enrollment: 3 (actual)

## Conditions studied

- Arginase I Deficiency
- Hyperargininemia

## Interventions

- **DRUG:** Pegzilarginase

## Key facts

- **NCT ID:** NCT05676853
- **Lead sponsor:** Aeglea Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-04-04
- **Primary completion:** 2023-04-27
- **Final completion:** 2023-04-27
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05676853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05676853, "A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05676853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*